Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Up 9.4% in October

Entera Bio Ltd. (NASDAQ:ENTX) saw a large increase in short interest in October. As of October 31st, there was short interest totalling 44,200 shares, an increase of 9.4% from the October 15th total of 40,400 shares. Based on an average trading volume of 31,500 shares, the days-to-cover ratio is currently 1.4 days.

Entera Bio Stock Down 4.0 %

ENTX stock traded down $0.07 during midday trading on Monday, reaching $1.66. 49,907 shares of the company’s stock traded hands, compared to its average volume of 124,391. The company has a 50-day simple moving average of $1.85 and a two-hundred day simple moving average of $1.91. Entera Bio has a 1-year low of $0.52 and a 1-year high of $3.35. The company has a market cap of $59.40 million, a price-to-earnings ratio of -6.65 and a beta of 1.58.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Virtu Financial LLC bought a new position in Entera Bio during the first quarter worth about $37,000. Signature Estate & Investment Advisors LLC acquired a new stake in shares of Entera Bio in the third quarter valued at about $90,000. Finally, Parkman Healthcare Partners LLC increased its position in shares of Entera Bio by 2.4% in the third quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock valued at $781,000 after acquiring an additional 9,558 shares during the last quarter. 14.11% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Entera Bio in a report on Monday, November 11th.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.